Hamilton Lane Advisors’s Forte Biosciences FBRX Stock Holding History

Hamilton Lane Advisors’s Portfolio FBRX Stock Details FBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-53	Closed	-$24K	–	41
2020 Q1	$24K	Hold	53	–	–	0.01%	36
2019 Q4	$11K	Hold	53	–	–	﹤0.01%	46
2019 Q3	$13K	Hold	53	–	–	0.01%	52
2019 Q2	$133K	Hold	53	–	–	0.07%	47
2019 Q1	$217K	Hold	53	–	–	0.11%	49
2018 Q4	$164K	Sell	53 -18	-25%	-$77.5K	0.14%	43
2018 Q3	$0	Hold	71	–	–	﹤0.01%	49
2018 Q2	$0	Hold	71	–	–	﹤0.01%	39
2018 Q1	$0	Buy	+71	New	+$329K	﹤0.01%	39

Other funds holding FBRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MYDA Advisors Woodmere, New York $672M AUM 71.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Hamilton Lane Advisors's FBRX Position: Q2 2020 in Review

Hamilton Lane Advisors sold out of Forte Biosciences (FBRX) in Q2 2020, closing a stake of 53 shares — an estimated $24K sold.

Hamilton Lane Advisors first reported a position in FBRX in Q1 2018 and held it in 9 quarters. The position peaked at $217K in Q1 2019. 27 funds tracked by Wall St. Rank hold FBRX as of Q2 2020.

Hamilton Lane Advisors reported no remaining Forte Biosciences position as of Q2 2020 after selling out during the quarter.
Hamilton Lane Advisors sold 53 Forte Biosciences shares in Q2 2020, an estimated $24K.
Hamilton Lane Advisors first reported a position in Forte Biosciences in Q1 2018 and held it in 9 quarters.
Hamilton Lane Advisors's Forte Biosciences position peaked at $217K in Q1 2019.
27 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2020.

Based on Hamilton Lane Advisors's 13F filing for Q2 2020, filed 16 Jul 2020.